PfizerPFE

Pfizer (PFE) is active in oncology, with regulatory documents detailing findings for IBRANCE (palbociclib) in combination with letrozole. In Study 1 (PALOMA-2), this combination was associated with various adverse events. For instance, neutropenia (all grades) was observed in 80% of patients, with Grade 3 neutropenia occurring in 56% and Grade 4 in 10%. Infections (all grades) were reported in 60% of patients, including 6% Grade 3 and 1% Grade 4. Leukopenia (all grades) incidence was 39%, with 24% Grade 3 and 1% Grade 4. Fatigue (all grades) was seen in 37% of patients, with 2% experiencing Grade 3 fatigue.

Other notable adverse events in Study 1 (PALOMA-2) for IBRANCE plus letrozole included nausea (all grades) at 35%, with less than 1% experiencing Grade 3 nausea. Stomatitis (all grades) occurred in 30% of patients, with 1% being Grade 3. Anemia (all grades) was reported in 24% of patients, with 5% Grade 3 and less than 1% Grade 4. Alopecia (all grades) had an incidence of 33%, while diarrhea (all grades) was 26%, with 1% Grade 3. Thrombocytopenia (all grades) was observed in 16% of patients, with 1% Grade 3 and less than 1% Grade 4. Rash (all grades) had an incidence of 18%, with 1% Grade 3 and 0% Grade 4. Vomiting (all grades) was 16%, with 1% Grade 3 and 0% Grade 4. Decreased appetite (all grades) was 15%, with 1% Grade 3 and 0% Grade 4. Asthenia (all grades) was 17%, with 2% Grade 3 and 0% Grade 4.